845 reports of this reaction
1.8% of all IMATINIB MESYLATE reports
#11 most reported adverse reaction
NEOPLASM MALIGNANT is the #11 most commonly reported adverse reaction for IMATINIB MESYLATE, manufactured by Novartis Pharmaceuticals Corporation. There are 845 FDA adverse event reports linking IMATINIB MESYLATE to NEOPLASM MALIGNANT. This represents approximately 1.8% of all 47,520 adverse event reports for this drug.
Patients taking IMATINIB MESYLATE who experience neoplasm malignant should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NEOPLASM MALIGNANT is a less commonly reported adverse event for IMATINIB MESYLATE, but still significant enough to appear in the safety profile.
In addition to neoplasm malignant, the following adverse reactions have been reported for IMATINIB MESYLATE:
The following drugs have also been linked to neoplasm malignant in FDA adverse event reports:
NEOPLASM MALIGNANT has been reported as an adverse event in 845 FDA reports for IMATINIB MESYLATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
NEOPLASM MALIGNANT accounts for approximately 1.8% of all adverse event reports for IMATINIB MESYLATE, making it a notable side effect.
If you experience neoplasm malignant while taking IMATINIB MESYLATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.